<DOC>
	<DOCNO>NCT02653300</DOCNO>
	<brief_summary>This open , pilot study use oral ORMD-0801 insulin formulation patient NASH confirm type 2 DM pre-diabetes . The study consist Screening , placebo run-in , treatment phase end-of-study phase .</brief_summary>
	<brief_title>A Pilot Study Assess Safety Oral Insulin Patients With Nonalcolholic Steatohepatitis ( NASH )</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Known type 2 DM accord American Diabetic Association ( one three need ) : Fasting Plasma Glucose ≥126 mg/dl 2h postprandial ( PG ) follow 75g OGTT ≥ 200 mg/dl HbA1C &gt; 5.7 % treatment metformin Abdominal ultrasound ( US ) prove fatty liver perform within 6 month randomization , confirm central US . Fat concentration liver S2 ( moderate steatosis , 632 % hepatocytes steatosis ) measure Fibromax . Signature write informed consent . Negative pregnancy test study entry females child bear potential . Females must negative urine pregnancy test result screening , prior start runin period , initiation active dosing . A negative urine serum pregnancy test must obtain prior active dosing . Males females childbearing potential must use two method contraception . Females nonchildbearing potential define postmenopausal ) 24 month since last menstrual cycle menopausal level FSH , b ) surgically menopausal . For hypertensive patient , hypertension must control stable dose antihypertensive medication least 2 month prior screen BP &lt; 150/ &lt; 95 mmHg Patients previously treat vitamin E ( &gt; 400IU/day ) . Glycaemia must control ( Glycosylated Hemoglobin A1C ≤9 % ) HbA1C increment exceed 1 % 6 month prior enrolment ) . Patients active ( acute chronic ) liver disease NASH ( e.g . viral hepatitis , genetic hemochromatosis , Wilson disease , alpha 1antitripsin deficiency , alcohol liver disease , drug induce liver disease ) time randomization . ALT AST ≥ 2 time ULN Abnormal synthetic liver function ( serum albumin ≤3.5gm % , INR &gt; 1.3 ) . Known alcohol and/or drug abuse dependence last five year . Weight &gt; 120 Kg Known history presence clinically significant cardiovascular , gastrointestinal , metabolic ( diabetes mellitus ) , neurologic , pulmonary , endocrine , psychiatric , neoplastic disorder nephrotic syndrome . History presence disease condition know interfere absorption , distribution , metabolism excretion drug include bile salt metabolite ( e.g . inflammatory bowel disease ( IBD ) , previous intestinal ( ileal colonic ) operation , chronic pancreatitis , celiac disease previous vagotomy . Weight loss 5 % within 6 month prior randomization . History bariatric surgery . Uncontrolled blood pressure BP ≥150/95 . Non type 2 DM ( type I , endocrinopathy , genetic syndrome etc ) . Patients HIV . Daily alcohol intake &gt; 20 g/day woman &gt; 30 g/day men . Treatment antidiabetic medication metformin , DPP4 inhibitor , GLP1 receptor agonist , TZDs , etc . Metformin , Fibrates , Statins , provide stable dose last 6 month . Patients treat Valproic acid , Tamoxifen , Methotrexate , Amiodaron . Chronic treatment antibiotic ( e.g . Rifaximin ) . Homeopathic and/or Alternative treatment . Uncontrolled hypothyroidism define Thyroid Stimulating Hormone &gt; 2X upper limit normal ( UNLN ) . Patients renal dysfunction : eGFR &lt; 40 ml/min . Unexplained serum creatinine phosphokinase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>